Quantcast

Latest Immunosuppressants Stories

2014-10-22 12:30:14

Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA, Oct. 22, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring several data presentations on Cimzia(®) (certolizumab pegol) at the American College of Gastroenterology's (ACG) 2014 Annual Scientific Meeting in Philadelphia,...

2014-10-21 23:15:35

Ongoing and Recent Evidence Shows RA Patients Who Supplement Methotrexate With Folate Therapy Have Better Outcomes, According To Makers of EnLyte With Delta Folate. Sunset, LA (PRWEB) October 21, 2014 Over one million people in the U.S. suffer from rheumatoid arthritis (RA), an autoimmune disease marked by pain, swelling, and stiffness in the joints. The most common first line treatment for RA is methotrexate, a prescription medication belonging to the class of drugs knows as DMARDS....

2014-10-20 16:27:09

- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 EAST HANOVER, N.J., Oct. 20, 2014 /PRNewswire/ -- Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) today voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment...

2014-10-20 08:31:41

First Patient Enrolled in PLATINUM Diversity Trial Evaluating Performance in Women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease MARLBOROUGH, Mass., Oct. 20, 2014 /PRNewswire/ -- As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (NYSE: BSX) has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER((TM)) Everolimus-Eluting Platinum...

2014-10-20 08:30:43

TARRYTOWN, N.Y. and PARIS, Oct. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical...

2014-10-17 23:02:09

A California man filed a class action lawsuit against Immunex and Caremark CVS alleging that the pharmacy fails to properly refrigerate best-selling drug Enbrel when filling a mail order Caremark prescription. As a result, thousands of seniors and disabled persons may be using Enbrel that, based on the manufacturer’s own guidelines, should not be used and should be discarded immediately; the plaintiff further alleges that the unapproved Enbrel is ineffective in treating his arthritis...

2014-10-17 12:28:58

DALLAS, October 17, 2014 /PRNewswire/ -- The Middle East and Africa Solid Organ Transplant Immunosuppressant Industry 2014 Deep Research Report is of 120 pages and published in October 2014. This is a professional and depth research report on Middle East and Africa Countries Solid Organ Transplant Immunosuppressant industry. Complete report is available at...

2014-10-15 08:31:21

AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With No Systemic Exposure GHENT, Belgium, Oct. 15, 2014 /PRNewswire/ -- ActoGeniX, a clinical stage biopharmaceutical company, today announced positive results of a Phase 1 study in healthy volunteers of AG014, an oral administration of the anti-TNF-alpha antibody certolizumab for Inflammatory Bowel Disease (IBD). The Phase 1 study results show that the product is safe and well tolerated while providing...

2014-10-13 08:27:39

- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available[1],[2],[3] AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-10-08 12:28:53

Patient Shares For Newer Alternative MOA Agents Are Also Expected To Grow In The Next Six Months, According To Findings From Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that despite the increasing percentage of rheumatoid arthritis (RA) patients treated with agents with a newer mechanism of action (MOA), three-quarters of DMARD-failure RA patients who are naive to biologics/Pfizer's Xeljanz are still initiated on tumor necrosis...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.